Prostate cancer biomarkers: a practical review based on different clinical scenarios.
Traditionally, diagnosis and staging of prostate cancer (PCa) have been based on prostate-specific antigen (PSA) level, digital rectal examination (DRE), and transrectal ultrasound (TRUS) guided prostate biopsy. Biomarkers have been introduced into clinical practice to reduce the overdiagnosis and o...
| Publicado en: | Critical Reviews in Clinical Laboratory Sciences Vol. 59; no. 5; pp. 297 - 309 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
Aug2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157791799&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 157791799 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10408363 1AV jtl: Critical Reviews in Clinical Laboratory Sciences issn: 10408363 maglogo: Y pubinfo: dt: Aug2022 vid: 59 iid: 5 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 157791799 155420652 157791799 157791799 10.1080/10408363.2022.2033161 157791799 ppf: 297 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Prostate cancer biomarkers: a practical review based on different clinical scenarios. aug: au: Falagario, Ugo Giovanni Sanguedolce, Francesca Dovey, Zach Carbonara, Umberto Crocerossa, Fabio Papastefanou, George Autorino, Riccardo Recchia, Marco Ninivaggi, Antonella Busetto, Gian Maria Annese, Pasquale Carrieri, Giuseppe Cormio, Luigi affil: Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy sug: subj: Tumor Markers, Biological Prostatic Neoplasms Risk Factors Risk Assessment Prostatic Neoplasms Therapy Biopsy Prostatic Neoplasms Radiotherapy Prostatic Neoplasms Surgery Prostatectomy, Radical ab: Traditionally, diagnosis and staging of prostate cancer (PCa) have been based on prostate-specific antigen (PSA) level, digital rectal examination (DRE), and transrectal ultrasound (TRUS) guided prostate biopsy. Biomarkers have been introduced into clinical practice to reduce the overdiagnosis and overtreatment of low-grade PCa and increase the success of personalized therapies for high-grade and high-stage PCa. The purpose of this review was to describe available PCa biomarkers and examine their use in clinical practice. A nonsystematic literature review was performed using PubMed and Scopus to retrieve papers related to PCa biomarkers. In addition, we manually searched websites of major urological associations for PCa guidelines to evaluate available evidence and recommendations on the role of biomarkers and their potential contribution to PCa decision-making. In addition to PSA and its derivates, thirteen blood, urine, and tissue biomarkers are mentioned in various PCa guidelines. Retrospective studies have shown their utility in three main clinical scenarios: (1) deciding whether to perform a biopsy, (2) distinguishing patients who require active treatment from those who can benefit from active surveillance, and (3) defining a subset of high-risk PCa patients who can benefit from additional therapies after RP. Several validated PCa biomarkers have become commercially available in recent years. Guidelines now recommend offering these tests in situations in which the assay result, when considered in combination with routine clinical factors, is likely to affect management. However, the lack of direct comparisons and the unproven benefits, in terms of long-term survival and cost-effectiveness, prevent these biomarkers from being integrated into routine clinical use. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|